In addition, high B7‐H4 expression is linked with lower overall survival as compared to other BC cancer patients using TCGA database analysis (Figure S1Q, Supporting Information).[22] These results collectively establish a significant association between elevated B7‐H4 expression and poorer clinical outcomes in TNBC patients potentially receiving SG therapy, highlighting the importance of B7‐H4 as a potential therapeutic target to enhance the immune system's effectiveness with ADC treatment. This evidence concerns the gene VTCN1 and cancer.